NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes
- PMID: 20064286
- DOI: 10.6004/jnccn.2009.0082
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes
Abstract
The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force to critically review the evidence for iron chelation and the rationale for treatment of transfusional iron overload in patients with myelodysplastic syndromes (MDS). The task force was charged with addressing issues related to tissue iron toxicity; the role of MRI in assessing iron overload; the rationale and role of treating transfusional iron overload in patients with MDS; and the impact of iron overload on bone marrow transplantation. This report summarizes the background data and ensuing discussion from the NCCN Task Force meeting on transfusional iron overload in MDS.
Similar articles
-
Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.Int J Hematol. 2008 Jul;88(1):24-29. doi: 10.1007/s12185-008-0118-z. Epub 2008 Jun 27. Int J Hematol. 2008. PMID: 18581200 Free PMC article. Review.
-
New insights into transfusion-related iron toxicity: Implications for the oncologist.Crit Rev Oncol Hematol. 2016 Mar;99:261-71. doi: 10.1016/j.critrevonc.2015.11.017. Epub 2015 Nov 27. Crit Rev Oncol Hematol. 2016. PMID: 26806144 Review.
-
Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.Drugs. 2011 Jan 22;71(2):155-77. doi: 10.2165/11585280-000000000-00000. Drugs. 2011. PMID: 21275444 Review.
-
Iron overload in myelodysplastic syndromes (MDS).Int J Hematol. 2018 Jan;107(1):55-63. doi: 10.1007/s12185-017-2367-1. Epub 2017 Nov 25. Int J Hematol. 2018. PMID: 29177643 Review.
-
Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.Expert Rev Hematol. 2017 Jan;10(1):53-64. doi: 10.1080/17474086.2017.1268910. Epub 2016 Dec 16. Expert Rev Hematol. 2017. PMID: 27923273 Review.
Cited by
-
Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes.J Adv Pract Oncol. 2016 Nov-Dec;7(7):707-717. Epub 2016 Nov 1. J Adv Pract Oncol. 2016. PMID: 29670807 Free PMC article. Review.
-
Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice.Elife. 2023 Dec 28;12:e83103. doi: 10.7554/eLife.83103. Elife. 2023. PMID: 38153418 Free PMC article.
-
The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.Curr Hematol Malig Rep. 2011 Jun;6(2):136-44. doi: 10.1007/s11899-011-0084-z. Curr Hematol Malig Rep. 2011. PMID: 21373838 Review.
-
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.J Natl Compr Canc Netw. 2011 Jan;9(1):30-56. doi: 10.6004/jnccn.2011.0005. J Natl Compr Canc Netw. 2011. PMID: 21233243 Free PMC article.
-
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.Am J Hematol. 2017 Mar;92(3):297-310. doi: 10.1002/ajh.24637. Am J Hematol. 2017. PMID: 28188970 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous